Miss K Breheny · Web view1996 PFIZER 148-106 A Phase 3 Randomized, Double-Blind,...

CURRICULUM VITAE

Assoc. Professor Chris G McMahon MB,BS (Monash) FAChSHM

BRIEF BIOGRAPHYChris G McMahon is a Consultant Sexual Health Physician and Fellow of the Royal Australian College of Physician’s Chapter of Sexual Medicine. He is an Associate Professor in the Faculty of Health Sciences, University of Sydney and the Director of the Australian Centre for Sexual Health in Sydney, Australia. Dr McMahon is a committee chairman for the WHO Second and Third International Consultation on Erectile and Sexual Dysfunction and a chairman of the International Society of Sexual Medicine (ISSM) medical and research standards committee. He is an Associate Editor of the Journal of Sexual Medicine, and a member of the editorial board of the International Journal of Sexual Health, Current Sexual Health Reports and an associate section editor of the British Journal of Urology. He is a referee for multiple international peer-reviewed medical journals including the Journal of Sexual Medicine, the Journal of Urology, Urology, European Journal of Urology, the British Journal of Urology, the International Journal of Impotence Research, the Medical Journal of Australia and Expert Opinion on Investigational Drugs. He is a member of several local, regional and international medical associations and a committee member of the International Society of Sexual Medicine (ISSM). He has been invited to lecture on sexual medicine worldwide and has published extensively on sexual health. He has published over 50 original research and invited review articles in peer reviewed international medical journals, and 12 book chapters. His recent research has focused on drug treatment for patients with refractory erectile dysfunction (ED) and drug treatment of premature ejaculation.

NAME: Dr Christopher Gordon McMahonDATE OF BIRTH: July 3 1951ADDRESS: Australian Centre for Sexual Health

Suite 2-4, 1A Berry Rd St Leonards NSW 2065TEL: IDD+ 61 2 9437 3906FAX: IDD+ 61 2 9906 5900EMAIL: [email protected]

EDUCATION

Pre-Medical1963-1968 Christian Brothers College St Kilda, Melbourne Australia

Undergraduate1969-1975 MB.,BS Monash University, Melbourne, Australia

Residency1976-1977 Internship Alfred Hospital Melbourne1977- 1978 Junior Surgical Resident Alfred Hospital Melbourne1978-1981 Surgical Registrar Mont Park Hospital Melbourne

Fellowships

1996 Fellow of the Australian College of Sexual Health Medicine2005 Foundation Fellow of the Royal Australian College of

Physician’s Chapter of Sexual Medicine

MEDICAL REGISTRATION

1997-1982 Victoria Australia1980 – current New South Wales Australia

POSITIONS

Associate Professor Faculty of Health Sciences, University of Sydney

Director Australian Centre for Sexual Health (1991-current)

Founding and Past President Australian Society of Impotence Medicine (ASIM)

Committee Chairman World Health Organisation (WHO) 3rd International Consultation on Sexual Dysfunction (2009)World Health Organisation (WHO) 2nd International Consultation on Sexual Dysfunction (2004)International Society of Sexual Medicine (ISSM) Standards Committee (2005-current)

Committee Member World Health Organisation (WHO) 1st International Consultation on Erectile Dysfunction (1998)

Chairman of Scientific Committee 19th Congress of World Association of Sexual Health (WAS) Sydney 2007

Associate Editor Journal of Sexual Medicine

Editorial Board Member Journal of Sexual MedicineJournal of Men’s HealthCurrent Sexual Health ReportsThe Journal of Medical Case Reports

Associate Section Editor British Journal of Urology

Committee Member International Society of Sexual Medicine (ISSM)

Scientific Publication Referee Journal of UrologyUrologyEuropean Journal of UrologyBritish Journal of Urology

of 27

Journal of Sexual MedicineInternational Journal of Impotence ResearchAsian Journal of AndrologyMedical Journal of AustraliaExpert Opinion on Investigational DrugsCurrent Sexual Health ReportsJournal of Men’s HealthFuture MedicineThe Journal of Medical Case Reports

Consultant/Member NSW Ministerial Committee of Enquiry into Impotence Treatment Services in NSW - 1998

Medical Referee NSW Health Care Complaints Commission (HCCC)

Medical Advisor Competition and Consumer Commission (ACCC)

Therapeutics Goods Administration Australia (TGA)

Australian Government Solicitors Department

NSW Department of Public Prosecutions (DPP)

MEDICAL SOCIETY MEMBERSHIPAmerican Urological Society (AUA)International Society of Sexual Medicine (ISSM)European Society of Sexual Medicine (ESSIM)African Society of Sexual and Impotence Research (ASSIR)Asian Pacific Society of Sexual Medicine (APSSM)Sexual Medicine Society of North America (SMSNA)Ku-ring-Gai Medical Association of Australia (KDMA)

TEACHING POSITIONS

1. Casual Lecturer in School of Medical Radiation Sciences, Faculty of Health Sciences and Radiology, University of Sydney (1996-2001)

2. Lecture in Diploma of Sexual Health (1998-current)3. Associate Professor Faculty of Health Sciences, University of Sydney

(2006-current)SUPERVISION OF RESEARCH FELLOWS

1. Supervision of clinical trial design, subject recruitment, study implementation, data collection, collation and statistical analysis, manuscript preparation, review, revision, submission and response to reviewer’s comments.

a. Kamal Touma 1998-1999i. 3 published papers (Publications #17,18,20)

b. Dr Ramin Samali 1999-2000i. 3 Published papers (Publications #21,22,24)

of 27

RESEARCH GRANTS

1998 - Grant from Astra Zeneca for Research Fellow - $25,000

1998 - Grant from UpJohn Pharmacia for Research Fellow - $25,000

1999 - Grant from Astra Zeneca for Research Fellow - $25,000

1999 - Grant from UpJohn Pharmacia for Research Fellow - $25,000

of 27

CURRENT RESEARCH INTERESTS

1. Salvage medical treatment of men with severe, treatment refractory erectile dysfunction

2. Pharmacological treatment of ejaculatory dysfunction

3. Integrated pharmacological/cognitive behavioral treatment of lifelong and acquired premature ejaculation

4. Prophylaxis of erectile function following nerve sparing radical prostatectomy for prostate cancer with tri-weekly tadalafil

CONSULTANT /MEMBER OF INDUSTRY MEDICAL ADVISORY BOARD

1. Australian medical advisory board for Caverject® – UpJohn Laboratories Australia – Member 1995-2000

2. Australian medical advisory board for MUSE® – Astra-Zeneca – Chairman 1998-2000

3. Medical adviser/consultant to Pfizer Australia 1998-current

4. Australian medical advisory board for Levitra® – Bayer Australia – Member 2001-current

5. Asia-Pacific medical advisory board for Levitra® – GSK Singapore – Member 2001-2004

6. Australian medical advisory board for Cialis® – Eli Lilly Australia – Chairman 2001-2006

7. Global medical advisory board for Cialis® – Eli Lilly Australia – Member 2001-2006

8. Australian medical advisory board for Dapoxetine® – Johnson & Johnson Australia – Chairman 2005-current

9. Global medical advisory board for Dapoxetine® – Johnson & Johnson Australia – Chairman 2001-current

10. Global medical advisory board for UK390,957 – Pfizer 2000-current

11. Medical adviser/consultant to Fauldings Laboratories – 2000

12. Medical adviser/consultant to Mayne Pharma – 2002-2003

13. Medical adviser/consultant to Plethora Solutions UK – 2005-current

of 27

PUBLICATIONS

1. The Human Immunodeficiency Virus presenting as multiple myeloma. Med.J.Aust. June, 1984

2. The Management of Impotence. Australian Doctor June 1989

3. The reliability of the papaverine test as a screening test for vascular disease in impotence. Int.J Imp Res (1990) 2, 133-142

4. The Dynamic Papaverine Test. Arteries et Vein Vol.X April 1991

5. Comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, Prostaglandin PGE1 alone and a combination of all three in the management of impotence. Int.J Imp Res 1991. 3: 133-142

6. The return of spontaneous erections after self injection of Prostaglandin E1. Int.J.Imp Res 1992;4: 179-186

7. The Treatment of varicose veins using the venous valve cuff. Phlebology 9:136-145, 1994

8. The Diagnosis of Impotence - CME file - Australian GP April 1994

9. The Treatment of Impotence - CME file - Australian GP May1994

10. An attempt to standardize the pharmacological diagnostic screening of vasculogenic impotence with prostaglandin E1. Int J Impot Res 1995 Jun;7(2):83-90

11. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction - International Journal of Impotence Research (1996) 8 (4) 233-236

12. Nonsurgical treatment of cavernosal venous leakage. Urology 1997 Jan;49(1):97-100

13. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998 Jun;159(6):1935-8

14. Correlation of penile duplex ultrasonography, PBI, DICC and angiography in the diagnosis of impotence.Int J Impot Res 1998 Sep;10(3):153-8

15. Treatment of premature ejaculation with sertraline hydrochloride. Int J Impot Res 1998 Sep;10(3):181-4; discussion 185

16. Treatment of post radical prostatectomy erectile dysfunction. Curr Opin Urol. 1998

of 27

17. Predictive value of patient history and correlation of nocturnal penile tumescence, colour duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction. Int J Impot Res 1999 11(1): 47-51

18. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single-blind placebo controlled crossover studies. J Urol 1999 Jun;161(6):1826-30

19. New treatment options for erectile dysfunction. Aust Fam Physician 1999 Aug;28(8):783-7, 789-90

20. Treatment of premature ejaculation with paroxetine hydrochloride. Int J Impot Res. 1999 Oct;11(5):241-245; discussion 246.

21. Treatment of intracorporeal injection non- with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol. 1999 Dec;162(6):1992-7; discussion 1997-8.

22. Pharmacological treatment of premature ejaculation. Curr Opin Urol. 1999. Nov; 9(6): 553-61.

23. Sildenafil. Med J Aust. 2000 Feb 21;172(4):192.

24. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol 2000 Oct;164(4):1192-1196

25. Erectile dysfunction. Med J Aust. 2000 Nov 6;173(9):492-7.

26. Neuroanatomy and Neurophysiology of Orgasm and Ejaculation. Book chapter. Andrologica Italia - accepted for publication

27. Topiglan MacroChem. Curr Opin Investig Drugs. 2002 Apr;3(4):602-6.

28. High flow priapism due to an arterio-lacunar fistula complicating initial veno-occlusive priapism. Int J Impot Res. 2002 Jun;14(3):195-6.

29. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002 Oct;168(4 Pt 1):1332-6.

30. High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction.Int J Impot Res. 2002 Dec;14(6):533-8.

31. Intermediate to long-term results of repairing incompetent multiple deep venous valves using external valvular stenting. ANZ J Surg. 2003 May;73(5):267-74.

of 27

32. Priapism associated with concurrent use of phosphodiesterase inhibitor drugs and intracavernous injection therapy. Int J Impot Res. 2003 Oct;15(5):383-4.

33. Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction Previously Unresponsive to On-demand Tadalafil. J Sex Med 2004; 1: 292–300

34. Disorder of Orgasm and Ejaculation in Men. J Sex Med 2004 1(1): 58-65

35. Comparison of efficacy and safety of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005, 3:415-427

36. A 6-month Study of the Efficacy and Safety of Oral Tadalafil in the Treatment of Erectile Dysfunction: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study. Int J Clin Pract. Vol 59, Issue 2, Page 143-149, February 2005

37. Efficacy of sildenafil citrate in men with premature ejaculation. J Sex Med, 2005. 2(3): 368.

38. Premature Ejaculation: Past Present and Future Perspectives. J Sex Med 2005 2 (suppl.2) 94-96

39. Efficacy, safety and tolerability of daily tadalafil in men with diabetes mellitus and erectile dysfunction previously unresponsive to on-demand tadalafil. Submitted to European Urology

40. AUA Guidelines for the Management of Premature Ejaculation. American Urological Association 2006

41. The Etiology and Management of Premature Ejaculation. Nature Clin Prac Urol 2005. 2 (9):426-433

42. New Agents in the Treatment of Premature Ejaculation (PE). Neuropsych Dis Treatment 2006:2(4) 489-503

43. Tolerance to the Therapeutic Effect of Tadalafil Does Not Occur During 6 Months of Treatment: A Randomized, Double-Blind, Placebo-Controlled Study in Men with Erectile Dysfunction – J Sex Med. 2006 May;3(3):504-11.

44. Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: a systematic review - BJU Int. 2006 Aug;98(2):259-72.

45. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol. 2006 Aug;50(2):215-7.

of 27

46. Vardenafil improved erectile function in a ‘real-life’ broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand – J Sex Med. 2006 Sep;3(5):892-900

47. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol. 2006 Aug;50(2):215-7

48. Premature Ejaculation. Indian Journal of Urology, 2007;23(2):97-109

49. Correlates to the Clinical Diagnosis of Premature Ejaculation: Results From a Large Observational Study of Men and Their Partners. J.Urol. 2006;177(3):1059-1064

50. Ejaculatory Latency vs. Patient-Reported Outcomes (PROs) as Study End Points in Premature Ejaculation Clinical Trials. Eur Urol. 2007 Aug;52(2):321-3.

51. Sexual Dysfunction in Men Receiving Methadone and Buprenorphine Maintenance Treatment. J Sex Med. 2008 Mar;5(3):684-92. Epub 2007 Dec 18.

52. Hypogonadism in Men Receiving Methadone and Buprenorphine Maintenance Treatment. Int J Androl. 2007 Oct 30. [Epub ahead of print]

53. An Evidence-Based Definition of Lifelong Premature Ejaculation: Report of the International Society for Sexual Medicine (ISSM) Ad Hoc Committee for the Definition of Premature Ejaculation. J Sex Med. 2008 May 6. [Epub ahead of print]

BOOK CHAPTERS

1. Local Pharmacological Treatment Modalities. In Erectile Dysfunction. Ed. Jardin A, Wagner G, Khoury S, Giuliano F, Padma Nathan H, Rosen R. Health Publications Ltd 2000

2. Androgens in Male Physiology. In Male and Female Sexual Dysfunction. Ed. Seftel A, Padma Nathan H, McMahon CG, Giuliano F, Althof SE. Mosby 2004

3. Physiology of the Ejaculatory Response. In Male and Female Sexual Dysfunction. Ed. Seftel A, Padma Nathan H, McMahon CG, Giuliano F, Althof SE. Mosby 2004

4. Treatment of Ejaculatory Dysfunction. In Male and Female Sexual Dysfunction. Ed. Seftel A, Padma Nathan H, McMahon CG, Giuliano F, Althof SE. Mosby 2004

5. Disorders of Orgasm and Ejaculation in Men. In Sexual Medicine: Sexual Dysfunctions in Men and Women. Ed. Lue T, Wagner G, Khoury S, Giuliano F, Padma Nathan H, Rosen R. Health Publications Ltd 2004

of 27

6. Pharmacological Strategies in the Management of Premature Ejaculation. In Current Clinical Urology: Oral Drug Therapy of Sexual Dysfunction: A Guide to Clinical Management. Ed. Broderick GA. The Humana Press 2004

7. Evaluation and Therapy for Ejaculatory Disorders. In Atlas of Male Sexual Dysfunction. Ed. Lue TF. Current Medicine 2004

8. Clinical Manual of Sexual Medicine: Sexual Dysfunction in Men. Ed. Lue T, Khoury S, Giuliano F, Rosen R. Health Publications Ltd 2004

9. Ejaculatory Dysfunction. In. Male Sexual Function. A Guide to Clinical Management. Ed. J.J. Mulcahy; Pub. Humana Press Inc., Totowa, New Jersey, 2005 in press

10. Ejaculatory Dysfunction. In. Sexual Medicine. Standards in Clinical Practice. Ed. H.Porst, J Buvat. Blackwell, 2006

11. Premature Ejaculation. In. Handbook of Psychiatry. Ed. Rowland D, Incrocci, L. In Press 2006

12. Medical Treatment of Ejaculatory Dysfunction. In. Textbook of Erectile Dysfunction. Ed Carson C, Goldstein I, Kirby R. In Press 2006

13. Erectile Dysfunction-Fast Facts – Health Press UK 2008

PRESENTATIONS AT LOCAL /REGIONAL OR INTERNATIONAL SCIENTIFIC MEETINGS

INVITED/KEYNOTE SPEAKER

1. External valvuloplasty in the management of Chronic Deep Venous Disease (CDVI) of the lower limb. Annual Meeting of the American Phlebology Society, Kansa USA, 1988

2. The treatment of Impotence. Annual meeting of the Australian Society of Sexual Educators, Researchers and Therapists (ASSERT), Sydney 1989

3. The Office Evaluation of Impotence. International Symposium on the Management of Impotence, St Vincent’s Clinic, Sydney Australia, Nov. 1991

4. The Investigation of Impotence- Annual meeting of the Australian Society of Sexual Educators, Researchers and Therapists (ASSERT) Sydney 1992

5. Impotence and its Treatment - Australian Diploma of Sexual Health, Sydney University April 1993

6. The Management of Impotence - Annual Meeting if the Royal Australian College of General Practitioners (RACGP), Sydney Australia July 1993

7. How I Treat Impotence -Internal Medicine Update Course, Faculty of Medicine, University of New South Wales September 1993

of 27

8. Assessing and Treating Male Sexual Dysfunction- Postgraduate Update meeting at Westmead Hospital, Westmead Sydney, September 1993

9. The Office Investigation of Impotence- Postgraduate Update meeting of the Royal North Shore Hospital Sydney March 1993

10. How I Treat Impotence - Annual Scientific Meeting of Ku-Ring-Gai Medical Association (KDMA) , Palm Cove QLD, Sept. 1994

11. The Anatomy, Physiology, Pathophysiology and Diagnosis of Erectile Dysfunction - Annual Meeting of the Australian Sexual Health Society, Terrigal, May 7 1995

12. Treatment of Premature ejaculation with Sertraline - 5th Biennial Asian Pacific Meeting on Impotence, Annual Meeting of the Asian Pacific Society for Impotence Research (APSIR), Perth November 1995

13. The Medical Management of Erectile Dysfunction - University of Sydney Postgraduate Medical Committee Macquarie Hospital Sydney May 21 1995

14. The Medical Management of Erectile Dysfunction - University of Sydney Postgraduate Medical Committee, St Johns College Sydney May 13 1995

15. The Diagnosis and Treatment of Erectile Dysfunction - Annual Meeting if the Royal Australian College of General Practitioners (RACGP), Canberra May 27 1995

16. The Medical Management of Erectile Dysfunction - Sexual Health Workshop, Royal Australian College of General Practitioners (RACGP),(RACGP), Orange NSW Australia June 4 1995

17. Investigation of Erectile Dysfunction by penile duplex Doppler ultrasound - Ultrasound in Urology Symposium. Faculty of Health Sciences and Radiology, University of Sydney, April 1995

18. The Medical Management of Erectile Dysfunction- Sexual Health Workshop, Royal Australian College of General Practitioners (RACGP) - Gold Coast Division, February 1996

19. The Importance of Accurate Diagnosis in the selection of Treatment for ED? - 6th Biennial Asia Pacific Meeting on Impotence. Annual Scientific Meeting of Asian Pacific Society of Impotence Research (APSIR ) Kuala Lumpur, Malaysia October 1997

20. Is Accurate Diagnosis important in the selection of Treatment for ED? - 2nd Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Madrid, Spain October 1997

21. Treatment of erectile failure with a combination of Vasoactive Intestinal Peptide and Phentolamine mesylate - 2nd Annual Scientific

of 27

Meeting of the European Society of Impotence Research (ESSIR) Madrid, Spain October 1997

22. Management of ED “Down-Under” - 8th World Meeting on Impotence, International Society of Impotence Research (ISSIR) Amsterdam August 1998

23. New developments in the management of ED - Annual General Meeting of the Canterbury Division of General Practice, Sydney Australia September 9 1998

24. The Pharmacological Treatment of Premature Ejaculation - 7th Biennial Asia Pacific Meeting on Impotence, Asian Pacific Society of Impotence Research (APSIR ) Tokyo October 26 1999

25. Pharmacological Treatment of ejaculatory Dysfunction. - 2nd Annual Meeting of the African Society of Impotence Research (ASSIR), Cairo Egypt Feb. 1999

26. The pathophysiological basis of erectile dysfunction. - 2nd Annual Meeting of the African Society of Impotence Research (ASSIR), Cairo Egypt Feb. 1999

27. The current role of sildenafil in the management of ED- Hunter Postgraduate Medical Institute. Men’s Health Update IX Newcastle, October 1999

28. New developments in the management of ED-Annual General Meeting of the Northern Rivers Division of General Practice, Tamworth NSW Australia September 1999

29. The Andropause-Annual General Meeting of the Northern Rivers Division of General Practice, Tamworth NSW Australia September 1999

30. Erectile Dysfunction: Causes of and consequences in Men’s Health. - 3rd National meeting on Men’s Health Alice Springs October 1999

31. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction - 9th World meeting on Impotence, International Society of impotence Research (ISSIR) Perth WA November 2000

32. New Horizons in ED Therapy - 9th World meeting on Impotence, International Society of impotence Research (ISSIR) Perth WA Australia November 2000

33. Pharmacological treatment of premature ejaculation- 9th World meeting on Impotence, International Society of impotence Research (ISSIR) Perth WA Australia November 2000

of 27

34. New developments in the management of ED - Annual General Meeting of the Shoalhaven Medical Society, Nowra NSW Australia October 2000

35. Advances in the Treatment of Erectile Dysfunction- Symposium ANZAC Research Institute “The Ageing Male”, Sydney 2001

36. Premature Ejaculation: Is it a Neurogenic Disorder?? - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

37. New Horizons in ED Therapy - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

38. Tadalafil (IC351): A Breakthrough in the Treatment of Erectile Dysfunction - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

39. Premature ejaculation: is it a neurogenic disorder? - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

40. Premature Ejaculation -2002 Sexual Health Global Research & Investigators' Conference, Orlando Fl USA May 25, 2002

41. The neurophysiology of ejaculation - 5th meeting of the European Society of Sexual and Impotence Research (ESSIR) Hamburg, Germany December 1-4 2002

42. Impotence and its Treatment - Annual Scientific Meeting of Canberra Family Planning Association, Canberra ACT Australia, April 1992

43. The Treatment of ED - Hunter Postgraduate Medical Institute. Men’s Health Update XII Newcastle, NSW Australia 2002

44. Erectile Dysfunction in the Light of PDE inhibition - Sexual Dysfunction Symposium? National Uni. Singapore, Singapore, November 14-15, 2002

45. Understanding Premature Ejaculation - Sexual Dysfunction Symposium National Uni. Singapore, Singapore, November 14-15, 2002

46. The Management of Premature Ejaculation - Asian View Meeting on Sexual Dysfunction. Hanoi, Vietnam - September 23 2002

47. Cialis: The Australian Experience - Eli Lilly Global General Medical Conference Indianapolis USA 2002

48. Oral Treatment of ED - Annual Scientific Meeting of South Australian Chapter of Australasian Urological Society (USA) - Adelaide November 16 2002

of 27

49. Treatment of Ejaculatory Dysfunction - Annual Scientific Meeting of South Australian Chapter of Australasian Urological Society (USA) - Adelaide November 16 2002

50. Diabetics with ED - Annual Scientific Meeting of the Australian Diabetic Educators Society, Canberra ACT Australia May 3 2003

51. Premature Ejaculation - Annual Meeting of Sexual Medicine Society of North America (SMSNA) Chicago USA - April 27 2003

52. Disorders of Ejaculation and Orgasm in Men - World Health Organization (WHO) 2nd International Consultation on Erectile and Sexual Dysfunction? Paris France - June 28th to July 2nd , 2003

53. Sexual Dysfunction Following Treatment for Prostate Cancer and its Management - The Australian Genitourinary Oncology Society Sydney NSW Australia 2003

54. Pharmacological Treatment of Rapid Ejaculation - 11th World Congress of the International Society of Sexual Medicine (ISSM) - Buenos Aires, Argentina 2004

55. Flexible Vardenafil Dosing In Australian And New Zealand Males With Erectile Dysfunction - Annual Meeting of Urological Society of Australasia (USA), Newcastle Australia 2004

56. Maximising the safe and efficacious use of phosphodiesterase 5 inhibitors -10th Biennial Meeting on Impotence, Asia Pacific Society for Sexual and Impotence Research (APSSIR) Cairns QLD Australia 2005

57. The Journal of Sexual Medicine Debate: “Psychologic therapy is preferred over medical therapy in premature ejaculation” - 10th Biennial Meeting on Impotence, Asia Pacific Society for Sexual and Impotence Research (APSSIR) Cairns QLD Australia 2005

58. Sexual satisfaction for couples in Bayer Symposium: Helping Couples Stay Connected - A Paradigm in ED Management- 10th Biennial Meeting on Impotence, Asia Pacific Society for Sexual and Impotence Research (APSSIR) Cairns QLD Australia 2005

59. Sexual Dysfunction Following Treatment for Prostate Cancer and its Management - The Australian Genitourinary Oncology Society Sydney NSW Australia 2005

60. PDE-5 Inhibitors in PE-Outcomes in Primary and Secondary PE - Annual Meeting of the Sexual Medicine Society of North America (SMSNA) , Boca Raton FL USA 2005

61. SSRIs and Management of PE - Annual Meeting of the Sexual Medicine Society of North America (SMSNA), Boca Raton FL USA 2005

of 27

62. Premature ejaculation – Korean Andrology Society Annual Scientific Meeting March 31, 2006 Seoul South Korea

63. Treatment of Premature Ejaculation: Medical vs. Behavioural Therapy – Debate Moderator, Annual Meeting of American Urological Association (AUA) 2006

64. Intravaginal Latency Time is Not the Only Assessment Tool of Premature Ejaculation-12th World Congress of the International Society of Sexual Medicine (ISSM)-Cairo, Egypt 2006

65. Treatment of Premature Ejaculation: Drugs, Behavioral Therapy, or Multimodal Therapy – Chairman and Faculty Member-12th World Congress of the International Society of Sexual Medicine (ISSM)-Cairo, Egypt 2006

66. Premature Ejaculation - 9th Meeting of the European Society for Sexual Medicine, Vienna Austria Dec 2006

67. Intravaginal Latency Time is Not the Only Assessment Tool of Premature Ejaculation. 18th Congress of the World Association of Sexual Health Sydney Australia April 2007

68. Pharmacological Treatment of Premature Ejaculation. 18th Congress of the World Association of Sexual Health Sydney Australia April 2007

PRESENTATIONS

1. The role of the office papaverine test in the assessment of impotence- Annual Meeting of the Urological Society of Australasia (USA) Melbourne 1988

2. The Revised dynamic papaverine test and its role in the evaluation of impotence-First International Symposium on Pharmacological Erection. Paris. France Nov. 1989.

3. A Comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, Prostaglandin PGE1 alone and a combination of all three in the management of impotence. 3rd Biennial Asian Pacific Meeting on Impotence, Asian Pacific Society of Impotence Research (APSIR) , Taiwan, 1991

4. Comparison of the response to the intracavernosal injection of a combination of papaverine and phentolamine, Prostaglandin PGE1 alone and a combination of all three in the management of impotence. Annual Meeting of American Urological Association (AUA) 1991

5. Comparison of the response of intracavernosal injection of differing doses of Prostaglandin PGE1 in an attempt to standardise the pharmacological diagnosis of impotence. Annual Meeting of American Urological Association (AUA), Washington DC, 1992

of 27

6. The return of spontaneous erections after self injection of Prostaglandin E1. Annual Meeting of the International Society for Impotence Research (ISSIR) Milan, Italy 1992.

7. Comparison of Duplex Ultrasonography, DICC and angiography in the diagnosis of vasculogenic impotence - 4th Biennial Asian Pacific Meeting on Impotence, Asian Pacific Society of Impotence Research (APSIR ) Bali Indonesia 1993.

8. Correlation of Colour Duplex Ultrasonography, DICC and Phalloangiography in the diagnosis of vasculogenic impotence. 89th Annual Meeting of the American Urological Association (AUA), San Francisco CA, USA, 1994

9. Colour Duplex Ultrasonography, DICC and Phalloangiography in the diagnosis of vasculogenic impotence - VI International Meeting on Impotence Research, International Society of impotence Research (ISSIR) Singapore 1994

10. Comparison of Prostaglandin E1 and Papaverine Self Injection Program Drop Out Rates - VI International Meeting on Impotence Research, Singapore 1994

11. The Results Of Extensive Venous Ligation Surgery - VI International Meeting on Impotence Research, International Society of impotence Research (ISSIR), Singapore 1994

12. The Results Of Non-Surgical Treatment Of Cavernosal Venous Leakage - VI International Meeting on Impotence Research, International Society of impotence Research (ISSIR), Singapore 1994

13. Treatment of erectile failure with a combination of Vasoactive Intestinal Peptide and Phentolamine mesylate - 5th Biennial Asian Pacific Meeting on Impotence, Annual Meeting of the Asian Pacific Society for Impotence Research (APSIR), Perth November 1995

14. Treatment of erectile failure with a combination of Vasoactive Intestinal Peptide and Phentolamine mesylate - 5th World Conference on Impotence, International Society of Impotence Research (ISSIR) San Francisco USA November 1996

15. Treatment of premature ejaculation with Sertraline hydrochloride -

5th World Conference on Impotence, International Society of Impotence Research (ISSIR) San Francisco USA November 1996

16. Predictive value of patient history and correlation with NPT and

vascular investigations in the evaluation of erectile dysfunction- 5th World Conference on Impotence, International Society of Impotence Research (ISSIR) San Francisco USA November 1996

of 27

17. Correlation of patient history with NPT, Duplex Doppler ultrasonography and DICC- 3rd International Meeting on Corpus Cavernosum EMG, Rome Italy March 1996

18. Treatment of erectile failure with a combination of Vasoactive Intestinal Peptide and Phentolamine mesylate- 3rd International Meeting on Corpus Cavernosum EMG, Rome Italy March 1996

19. Predictive value of patient history and correlation of nocturnal penile tumescence, duplex Doppler ultrasonography and dynamic cavernosometry and cavernosography in the evaluation of erectile dysfunction - 6th Biennial Asia Pacific Meeting on Impotence. Annual Scientific Meeting of Asian Pacific Society of Impotence Research (APSIR ) Kuala Lumpur, Malaysia October 1997

20. Treatment of Peyronie's Disease with intralesional Verapamil Hydrochloride injections - 6th Biennial Asia Pacific Meeting on Impotence. Annual Scientific Meeting of Asian Pacific Society of Impotence Research (APSIR ) Kuala Lumpur, Malaysia October 1997

21. Treatment of premature ejaculation with paroxetine hydrochloride - 6th Biennial Asia Pacific Meeting on Impotence. Annual Scientific Meeting of Asian Pacific Society of Impotence Research (APSIR ) Kuala Lumpur, Malaysia October 1997

22. Treatment of premature ejaculation with Paroxetine hydrochloride - 8th World Meeting on Impotence, International Society of Impotence Research (ISSIR) Amsterdam August 1998

23. Partners of affected men - attitudes relating to erectile dysfunction - 7th Biennial Asia Pacific Meeting on Impotence, Asian Pacific Society of Impotence Research (APSIR ) Tokyo October 26 1999

24. How affected men get information about their erectile dysfunction - 7th Biennial Asia Pacific Meeting on Impotence, Asian Pacific Society of Impotence Research (APSIR ) Tokyo October 26 1999

25. Treatment of Intracorporal Injection Non-responders with Sildenafil Alone or in Combination with Polyagent Intracorporal Injections - 7th Biennial Asia Pacific Meeting on Impotence, Asian Pacific Society of Impotence Research (APSIR ) Tokyo October 26 1999

26. Colour flow duplex ultrasonography of the proximal cavernosal arteries - 94th Annual Scientific Meeting of American Urological Association (AUA) Annual Meeting Dallas TX USA 1999

27. Treatment of penile self injection non-responders with sildenafil - 94th Annual Scientific Meeting of American Urological Association (AUA) Annual Meeting Dallas TX USA 1999

28. Treatment of premature ejaculation with paroxetine hydrochloride as needed: 2 single blind placebo controlled crossover studies - 94th

of 27

Annual Scientific Meeting of American Urological Association (AUA) Annual Meeting Dallas TX USA 1999

29. A retrospective study of 672 patients with penile induration seen at the Australian Centre for Sexual Health (ACSH) from 1992-1999 - 9th World meeting on Impotence, International Society of impotence Research (ISSIR) Perth WA Australia November 2000

30. Treatment of intracorporal Injection non-responders with sildenafil alone or in combination with polyagent intracorporal injections - 9th World meeting on Impotence, International Society of impotence Research (ISSIR) Perth WA Australia November 2000

31. Colour flow duplex ultrasonography of the proximal cavernosal arteries - 9th World meeting on Impotence, International Society of impotence Research (ISSIR) Perth WA Australia November 200

32. High dose sildenafil as salvage therapy for erectile dysfunction - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

33. Correlation With Results of Neva in Men With Erectile Dysfunction With Rigicsan Nocturnal Penile Rigidity Testing, Penile Colour Duplex Doppler Ultrasonography And Dynamic Cavernosometry And Cavernsography - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

34. Long Term Results Of Treatment Of Premature Ejaculation With Selective Serotonin Re-Uptake Inhibitor (SSRI) Drugs - 4th Annual Scientific Meeting of the European Society of Impotence Research (ESSIR) Rome, Italy November 2001

35. High dose sildenafil as salvage therapy for erectile dysfunction - 10th meeting of the International Society of Sexual and Impotence Research (ISSIR) Montreal, Canada September 22-26 2002

36. Nocturnal Electrobioimpedance Volumetric Assessment (Neva) of Patients With Erectile Dysfunction - Correlation With Results of Neva in Men With Erectile Dysfunction With Rigicsan Nocturnal Penile Rigidity Testing, Penile Colour Duplex Doppler Ultrasonography And Dynamic Cavernosometry And Cavernsography - 10th meeting of the International Society of Sexual and Impotence Research (ISSIR) Montreal, Canada September 22-26 2002

37. Long term results of the treatment of premature ejaculation with SSRI drugs - 10th Annual Scientific Meeting of meeting of the International Society of Sexual and Impotence Research (ISSIR) Montreal, Canada September 22-26 2002

38. High Dose Sildenafil as Salvage Therapy for erectile dysfunction- 10th Annual Scientific Meeting of meeting of the International Society of Sexual and Impotence Research (ISSIR) Montreal, Canada September 22-26 2002

of 27

39. Efficacy and safety of tadalafil in men with erectile dysfunction - An integrated analysis of registration trials - 10th Annual Scientific Meeting of meeting of the International Society of Sexual and Impotence Research (ISSIR) Montreal, Canada September 22-26 2002

40. Efficacy and Safety of Daily Tadalafil in Men with Erectile Dysfunction previously unresponsive to “On-Demand” Tadalafil - 11th World Congress of the International Society of Sexual Medicine (ISSM) - Buenos Aires, Argentina 2004

41. Comparison of Efficacy and Safety of “On-Demand” Tadalafil and Daily Tadalafil for the Treatment of Erectile Dysfunction - 11th World Congress of the International Society of Sexual Medicine (ISSM) - Buenos Aires, Argentina 2004

42. Potential Predictors for Treatment Preference in Men with Erectile Dysfunction Taking Sildenafil and Tadalafil in an Open-label Switch Trial - 11th World Congress of the International Society of Sexual Medicine (ISSM) - Buenos Aires, Argentina 2004

43. Sustained Efficacy and Lack of Densenitization to tadalafil during a 6 month treatment period - Results of a randomised double blind placebo controlled trial - 11th World Congress of the International Society of Sexual Medicine (ISSM) - Buenos Aires, Argentina 2004

44. Vardenafil improved erectile function in a real-life broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand - Annual Scientific Meeting of the International Society of Sexual Medicine (ISSM) - Buenos Aires, Argentina 2004

45. Vardenafil improves treatment satisfaction and sexual pleasure in men with erectile dysfunction and their partners - 10th Biennial Meeting on Impotence, Asia Pacific Society for Sexual and Impotence Research (APSSIR) Cairns QLD Australia 2005

46. Vardenafil improves erection quality assessed by the novel erection quality scale in the broad population of men with erectile dysfunction - 10th Biennial Meeting on Impotence, Asia Pacific Society for Sexual and Impotence Research (APSSIR) Cairns QLD Australia 2005

47. Efficacy of PDE-5 Inhibitors in the Drug Treatment of Premature Ejaculation: A Systematic Review-12th World Congress of the International Society of Sexual Medicine (ISSM)-Cairo, Egypt 2006

of 27

INVITED PRESENTATIONS AT INDUSTRY FUNDED SYMPOSIA

1. Talking Sex with Patients Worksop - Sydney Australia 1999

2. Cialis: Clinical Experience - Eli Lilly Asian General Medical Conference Singapore 2003

3. Cialis: Freedom of Choice for Patients - Scientific Meeting of the Chinese Urological Association. Beijing China 2003

4. Cialis Choose the Moment Lunch - Scientific Meeting of the Indonesian Urological Association Meeting, Jakarta Indonesia

5. Cialis Choose the Moment Lunch - Scientific Meeting of the Indonesian Urological Association Meeting, Surabaya Indonesia

6. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Surfers Paradise QLD Australia, Feb 15-16 2003

7. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Albury, VIC Australia, May 21, 2003

8. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Lane Cove, Sydney, NSW Australia, May 20, 200

9. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Newcastle, NSW Australia, May 13, 2003

10. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Parramatta, Sydney NSW Australia, May 7, 2003

11. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Terrigal, NSW Australia, May 8, 2003

12. Levitra - A new potent and highly selective oral treatment for erectile dysfunction-ED Symposium sponsored by Bayer Australia Westin Hotel Sydney NSW Australia, May 6 2003

13. Tadalafil A new choice for first-line ED therapy - ED Symposium sponsored by Eli Lilly Singapore, Singapore, April 5-6 2003

14. Tadalafil A new choice for first-line ED therapy - ED Symposium sponsored by Eli Lilly Australia, Canberra, ACT Australia, March 11 2003

15. Tadalafil A new choice for first-line ED therapy - ED Symposium sponsored by Eli Lilly Australia - Maroochydore QLD Australia, April 8, 2003

of 27

16. Tadalafil A new choice for first-line ED therapy - ED Symposium sponsored by Eli Lilly Australia - Wollongong NSW Australia, March 13 2003

17. Tadalafil A new choice for first-line ED therapy - ED Symposium sponsored by Eli Lilly Australia - Sydney NSW Australia, - February 27 2003

18. Treating Erectile Dysfunction- What’s New on the Horizon - Scientific Meeting of Urological society, of Singapore, Singapore 2004

19. Treating Erectile Dysfunction- Whits New on the Horizon - Scientific Meeting of Malaysian Urological society, Singapore, Melaka Malaysia 2004

20. Treating Erectile Dysfunction- What’s New on the Horizon - Scientific Meeting of Malaysian Urological society, Singapore, Kuala Lumpa Malaysia 2004

21. Treating Erectile Dysfunction- What’s New on the Horizon - Scientific Meeting of Malaysian Urological society, Singapore, Jahor Baharu, Malaysia 2004

22. Treating Erectile Dysfunction- What’s New on the Horizon - Scientific Meeting of Malaysian Brunei society, Singapore, Kota Kinabalu, Brunei 2004

23. Treating Erectile Dysfunction- What’s New on the Horizon - Scientific Meeting of Malaysian Urological society, Singapore, Kuching Malaysia 2004

24. Treating Erectile Dysfunction- What’s New on the Horizon - Scientific Meeting of Malaysian Urological society, Singapore, Kuantan Malaysia 2004

25. Erectile Dysfunction and Introduction to a Novel PDE5 Inhibitor - Annual Scientific Meeting of the Thai Urological Society, Bangkok Thailand 2004

69. Helping Couples Stay Connected-A Paradigm in ED Management. 10th Biennial Meeting on Impotence, Asia Pacific Society for Sexual and Impotence Research (APSSIR) Cairns QLD Australia 2005

70. Erectile Dysfunction –Management in General Practice – Ridges Hotel Sydney March 4, 2006

71. Erectile Dysfunction–Management in General Practice – Rafferty’s Resort, Lake Macquarie NSW Australia March 11, 2006

72. Beyond Erectile Dysfunction– Strathfield NSW Australia August 8, 2006

of 27

73. Beyond Erectile Dysfunction– Brighton-Le-Sands NSW Australia August 29, 2006

of 27

CONVENED MEETINGS

1. Impotence and its Treatment - A Symposium- Sydney Australia, October 1990

2. Impotence and its Treatment - A Symposium. Auckland New Zealand Nov.1990.

3. First Annual Meeting of the Australian Society of Impotence Medicine (ASIM) - Sydney 1998

4. First Annual Meeting of the Australian Society of Impotence Medicine (ASIM) - Sydney 1999

5. GP Management of Sexual Dysfunction - Manly Pacific Hotel 18/5/2004

6. GP Management of Sexual Dysfunction - Stamford Plaza Hotel Ryde 25/5/2004

7. GP Management of Sexual Dysfunction - Chatswood 15/10/2004

8. GP Management of Sexual Dysfunction – Chatswood 22/10/2004

9. XVIII World Congress of the World Association of Sexology (WAS) – Chairman of Scientific Committee. April 15-19, 2007

of 27

INVESTIGATOR IN INDUSTRY SPONSORED CLINICAL TRIALS

YEAR SPONSOR PROTOCOL NAME1996 PFIZER 148-106 A Phase 3 Randomized, Double-Blind,

Placebo-Controlled Study of the Efficacy and Safety of Sildenafil citrate administered “On Demand” to Patients with Erectile Dysfunction

1998 ICOS-LILLY 3H6D-MC-LVCQ A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of IC351 (LY450190) Administered Over 6 Months “On Demand” to Patients with Erectile Dysfunction

1998 ICOS-LILLY H6D-VI-LVFH Switching from Sildenafil Citrate to Tadalafil (LY450190) in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference

1998 ICOS-LILLY 3H6D-MC-LVDR A Six-Month, Open-Label Study of “On Demand” Therapy with IC351 (LY450190) for the Treatment of Male Erectile Dysfunction

1998 SENETEC PLC VP014 An Open label extension study to evaluate Longer term safety and continued effIcacy of Invicorp in the treatment of Erectile Dysfunction

2000 BAYER BAY 38-9456/10125 A Randomised, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the Safety and Tolerability of the Phosphodiesterase Type V Inhibitor BAY 38 - 9456 in the Treatment of Patients with Erectile Dysfunction.

2000 LILLY B7A-MC-MBCI A Phase 3, multi-centre, parallel, randomised, double blind, placebo controlled, 6 month study with a 6 month extended treatment phase to investigate the efficacy and safety of a Phosphokinase C inhibitor LY333531 in the treatment of diabetic males with Erectile dysfunction

2000 ABBOTT W99-323 An Open-Label Safety and Efficacy Study of 2,3, and 4mg Uprima tablets in the treatment of male erectile dysfunction

2001 BAYER BAY 38-9456/10573 A Randomised, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Extension of Study 10125 to Investigate the Safety and Tolerability of the Phosphodiesterase Type V Inhibitor Vardenafil in the Treatment of Patients with Erectile Dysfunction over a total Exposure of 24 Months

YEAR SPONSOR PROTOCOL NAME2001 PFIZER A3711007 (UK-369,003) A phase II, double blind, placebo-

controlled, parallel group, multi-centre dose-response study to assess the efficacy, safety and toleration of UK-369,003 taken as required (prn) prior to sexual activity by subjects with erectile dysfunction (ED).

2001 PFIZER A1481071 A Phase 2 multi-center, placebo controlled

of 27

trial to assess the safety and efficacy of oral sildenafil citrate in the treatment of men with premature ejaculation.

2002 BAYER SB-782528-001 [10898] A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible dose regimen compared to placebo in male erectile dysfunction subjects of broad etiology previously unresponsive to sildenafil therapy by history

2002 BAYER SB-782528-020 An open label, multicentre study to investigate the safety, tolerability and efficacy of vardenafil given on demand in males with erectile dysfunction

2002 GSK SB-782528-001 [10898] A randomised, double-Blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in a flexible dose regimen compared to placebo in male erectile dysfunction subjects of broad etiology previously unresponsive to sildenafil therapy by history

2002 GSK SB-782528-020 An open label, multicentre study to investigate the safety, tolerability and efficacy of vardenafil given on demand in males with erectile dysfunction

2002 PFIZER A3871014 A phase II, multi-centre, double-blind placebo-controlled, parallel group, study to assess the efficacy of oral UK-390,957 in out-patients with premature ejaculation.

2002 PHARMACIA 774-URO-0493-003 Dose Ranging Safety and Efficacy Study of PNU-142774E in Males with Erectile Dysfunction: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Sildenafil Comparison with 8 week in Home Treatment

2002 PFIZER A1481119 An International, Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Self-Esteem and Overall Relationships In Men With ED Treated With Viagra ®

YEAR SPONSOR PROTOCOL NAME2004 LILLY H6D-MC-LVFZ A Randomised, Double-Blind, Parallel-

Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5 mg and 5 mg) Administered Once Daily to Men with Diabetes Mellitus and Erectile Dysfunction

2004 GSK SB732528/021 A randomized, double-blind, parallel-group, placebo-controlled study evaluating the duration of efficacy and safety of VARDENAFIL administered for 10 weeks in a flexible-dose regimen compared to placebo in subjects with erectile dysfunction of broad etiology.

2004 GSK VAR100447 (START) A 4 week, randomised, double-blind,

of 27

double-dummy, parallel-group, active-controlled study evaluating the efficacy of 10mg vardenafil versus 10mg tadalafil when intercourse is attempted within 45 minutes of administration in subjects with mild/moderate to severe erectile dysfunction

2004 GSK VAR102372 (EXTEND) A pilot, randomized, double-blind, placebo-controlled, crossover study evaluating the efficacy and safety of Vardenafil versus placebo administered 12, 18 and 24 hours prior to initiation of sexual intercourse in subjects with erectile dysfunction.

2004 PFIZER A3871027 A phase IIB, multi-centre, double-blind placebo-controlled, parallel group, dose response study to assess the efficacy of oral UK-390,957 in men with premature ejaculation.

2004 QUINTILES V1.2 05072004 VIVA Validation Program 2005 PFIZER A1481195 An Open-Label Study To Evaluate

Treatment Responsiveness To The Quality Of Erection Questionnaire (QEQ) In Men With Erectile Dysfunction Treated With Viagra (Sildenafil Citrate)

2005 PFIZER A3871028 A Phase 2 multi-center, open label, long-term extension trial to assess the safety and sustained efficacy of oral UK 390,957 administered as required in adult men with premature ejaculation

2005 PFIZER A3871029 A phase 2, multi-centre, double-blind, placebo-controlled, flexible dose study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation

YEAR SPONSOR PROTOCOL NAME2005 JANSEN CILAG R096769-PRE-3003 A placebo-controlled, double blind,

randomized, parallel-group study of the efficacy and safety of Dapoxetine in the treatment of men with premature ejaculation.

2006 SOLVAY S176.3.104 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Testosterone Gel 1.62% for the Treatment of Hypogonadal Men

of 27

Signature: Date: Thursday, 18 May 2023

of 27

Miss K Breheny · Web view1996 PFIZER 148-106 A Phase 3 Randomized, Double-Blind,...

Documents

Transcript of Miss K Breheny · Web view1996 PFIZER 148-106 A Phase 3 Randomized, Double-Blind,...